Logo image of PCVX

VAXCYTE INC (PCVX) Stock Fundamental Analysis

USA - NASDAQ:PCVX - US92243G1085 - Common Stock

32.17 USD
-0.89 (-2.69%)
Last: 9/12/2025, 8:07:22 PM
32.17 USD
0 (0%)
After Hours: 9/12/2025, 8:07:22 PM
Fundamental Rating

3

Overall PCVX gets a fundamental rating of 3 out of 10. We evaluated PCVX against 541 industry peers in the Biotechnology industry. While PCVX has a great health rating, there are worries on its profitability. PCVX has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year PCVX has reported negative net income.
In the past year PCVX has reported a negative cash flow from operations.
In the past 5 years PCVX always reported negative net income.
PCVX had a negative operating cash flow in each of the past 5 years.
PCVX Yearly Net Income VS EBIT VS OCF VS FCFPCVX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 -100M -200M -300M -400M -500M

1.2 Ratios

PCVX has a Return On Assets of -16.56%. This is in the better half of the industry: PCVX outperforms 79.67% of its industry peers.
PCVX has a better Return On Equity (-17.83%) than 86.14% of its industry peers.
Industry RankSector Rank
ROA -16.56%
ROE -17.83%
ROIC N/A
ROA(3y)-21.33%
ROA(5y)-23.51%
ROE(3y)-23.3%
ROE(5y)-26.19%
ROIC(3y)N/A
ROIC(5y)N/A
PCVX Yearly ROA, ROE, ROICPCVX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for PCVX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PCVX Yearly Profit, Operating, Gross MarginsPCVX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

8

2. Health

2.1 Basic Checks

Compared to 1 year ago, PCVX has more shares outstanding
Compared to 5 years ago, PCVX has more shares outstanding
There is no outstanding debt for PCVX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
PCVX Yearly Shares OutstandingPCVX Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
PCVX Yearly Total Debt VS Total AssetsPCVX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B

2.2 Solvency

PCVX has an Altman-Z score of 10.14. This indicates that PCVX is financially healthy and has little risk of bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 10.14, PCVX belongs to the top of the industry, outperforming 85.21% of the companies in the same industry.
There is no outstanding debt for PCVX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 10.14
ROIC/WACCN/A
WACCN/A
PCVX Yearly LT Debt VS Equity VS FCFPCVX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 1B 2B 3B

2.3 Liquidity

A Current Ratio of 11.11 indicates that PCVX has no problem at all paying its short term obligations.
With an excellent Current ratio value of 11.11, PCVX belongs to the best of the industry, outperforming 83.73% of the companies in the same industry.
PCVX has a Quick Ratio of 11.11. This indicates that PCVX is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 11.11, PCVX belongs to the top of the industry, outperforming 83.73% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 11.11
Quick Ratio 11.11
PCVX Yearly Current Assets VS Current LiabilitesPCVX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 12.31% over the past year.
EPS 1Y (TTM)12.31%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-10.91%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 8.15% on average over the next years. This is quite good.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-31.36%
EPS Next 2Y-25.06%
EPS Next 3Y-17.55%
EPS Next 5Y8.15%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
PCVX Yearly Revenue VS EstimatesPCVX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2027 2028 2029 2030 2031 2032 1B 2B 3B
PCVX Yearly EPS VS EstimatesPCVX Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 5 -5 10

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for PCVX. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for PCVX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PCVX Price Earnings VS Forward Price EarningsPCVX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PCVX Per share dataPCVX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 10 15 20

4.3 Compensation for Growth

A cheap valuation may be justified as PCVX's earnings are expected to decrease with -17.55% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-25.06%
EPS Next 3Y-17.55%

More info and screens

0

5. Dividend

5.1 Amount

PCVX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

VAXCYTE INC

NASDAQ:PCVX (9/12/2025, 8:07:22 PM)

After market: 32.17 0 (0%)

32.17

-0.89 (-2.69%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-06 2025-08-06/amc
Earnings (Next)11-03 2025-11-03
Inst Owners115.66%
Inst Owner Change2.46%
Ins Owners0.7%
Ins Owner Change8.5%
Market Cap4.18B
Analysts87.5
Price Target117.17 (264.22%)
Short Float %8.9%
Short Ratio7.89
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)0.32%
Min EPS beat(2)-2.1%
Max EPS beat(2)2.74%
EPS beat(4)3
Avg EPS beat(4)10.46%
Min EPS beat(4)-2.1%
Max EPS beat(4)28.3%
EPS beat(8)4
Avg EPS beat(8)-1.49%
EPS beat(12)6
Avg EPS beat(12)-0.3%
EPS beat(16)8
Avg EPS beat(16)-0.72%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-8.65%
PT rev (3m)-8.65%
EPS NQ rev (1m)-6.51%
EPS NQ rev (3m)-15.78%
EPS NY rev (1m)-2.28%
EPS NY rev (3m)-1.13%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.36
P/tB 1.36
EV/EBITDA N/A
EPS(TTM)-4.1
EYN/A
EPS(NY)-5.93
Fwd EYN/A
FCF(TTM)-4.34
FCFYN/A
OCF(TTM)-3.54
OCFYN/A
SpS0
BVpS23.66
TBVpS23.66
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -16.56%
ROE -17.83%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-21.33%
ROA(5y)-23.51%
ROE(3y)-23.3%
ROE(5y)-26.19%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 448.09%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 11.11
Quick Ratio 11.11
Altman-Z 10.14
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)548.71%
Cap/Depr(5y)418.57%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)12.31%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-10.91%
EPS Next Y-31.36%
EPS Next 2Y-25.06%
EPS Next 3Y-17.55%
EPS Next 5Y8.15%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-41.34%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-16.59%
EBIT Next 3Y-9.59%
EBIT Next 5YN/A
FCF growth 1Y-156.64%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-114.32%
OCF growth 3YN/A
OCF growth 5YN/A